Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Obesity Surgery
Erschienen in: Obesity Surgery 12/2021

23.09.2021 | Original Contributions

Surgery for Obesity and Weight-Related Diseases Changes the Inflammatory Profile in Women with Severe Obesity: a Randomized Controlled Clinical Trial

verfasst von: Alan Robson Trigueiro de Sousa, Wilson Rodrigues Freitas Junior, Eduardo Araujo Perez, Elias Jirjoss Ilias, Anderson Soares Silva, Vera Lucia Santos Alves, João Pedro Ribeiro Afonso, Miriã Cândida Oliveira, Adriano Luís Fonseca, Marcos Mota da Silva, Maria Eduarda Moreira Lino, Manoel Carneiro Oliveira Junior, Rodolfo Paula Vieira, Wilson José Sena Pedro, André Luis Lacerda Bachi, Giuseppe Insalaco, Carlos Alberto Malheiros, Luis Vicente Franco Oliveira

Erschienen in: Obesity Surgery | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction/Purpose

Obesity increases significantly every year worldwide. Since 1980, the prevalence of individuals with obesity has practically doubled. Obesity plays an important role in the pathophysiology of diseases that arise from a complex interaction of nutritional, genetic, and metabolic factors, characterizing a chronic inflammatory state. This study aimed to verify the systemic inflammatory response through the analysis of IGF-1, IL-23, and resistin levels and the lipid profile in severely obese women undergoing surgery for obesity and weight-related diseases.

Materials and Methods

This randomized controlled clinical trial includes female patients clinically diagnosed with severe obesity with an indication for bariatric surgery.

Results

In the initial evaluation, no significant difference was observed between the control (CG) and bariatric surgery (BSG) groups. The weight, BMI, systolic and diastolic blood pressures, total cholesterol, LDL, HDL, total non-HDL cholesterol, and glucose in BSG patients showed a significant change after surgery. Pre- and post-surgery levels of resistin, IGF-1, and IL-23 showed a significant difference in the BSG group, but only IL-23 was changed after 6 months in the CG.

Conclusion

The results of this study confirmed that weight loss induced by surgery for obesity and weight-related diseases improved the lipid profile and reduced the chronic inflammatory status in women with severe obesity.

Graphical abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1–253.
3.
4.
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998;6 Suppl 2:51S-209S. Erratum in: Obes Res 1998 Nov;6(6):464.
5.
Hu FB. Obesity epidemiology. Oxford: Oxford University Press; 2008. p. 498.CrossRef
6.
Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults 1980–2013: a systematic analysis. Lancet. 2014;384(9945):766–81.PubMedPubMedCentralCrossRef
7.
Mapa da Obesidade. Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica (Abeso). São Paulo; 2020. Available from: https://​abeso.​org.​br/​. Brazilian Portuguese. Accessed 2021 Aug 03
8.
9.
Poirier P. Adiposity and cardiovascular disease: are we using the right definition of obesity? Eur Heart J. 2007;28(17):2047–8.PubMedCrossRef
10.
Karczewski J, Śledzińska E, Baturo A, et al. Obesity, and inflammation. Eur Cytokine Netw. 2018;29(3):83–94.PubMedCrossRef
11.
12.
Chrysant SG. Pathophysiology and treatment of obesity-related hypertension. J Clin Hypertens (Greenwich). 2019;21(5):555–9.CrossRef
13.
Banerjee S, Talukdar I, Banerjee A, et al. Type II diabetes mellitus and obesity: common links, existing therapeutics and future developments. J Biosci. 2019;44(6):150.PubMedCrossRef
14.
Russel SM, Valle V, Spagni G, et al. Physiologic mechanisms of type II diabetes mellitus remission following bariatric surgery: a meta-analysis and clinical implications. J Gastrointest Surg. 2020;24(3):728–41.PubMedCrossRef
15.
Meurling IJ, Shea DO, Garvey JF. Obesity and sleep: a growing concern. Curr Opin Pulm Med. 2019;25(6):602–8.PubMedCrossRef
16.
Perez EA, Oliveira LVF, Freitas WR Jr, et al. Prevalence and severity of syndrome Z in women with metabolic syndrome on waiting list for bariatric surgery: a cross-sectional study. Diabetol Metab Syndr. 2017;20(9):72.CrossRef
17.
Scotece M, Conde J, López V, et al. Adiponectin and leptin: new targets in inflammation. Basic Clin Pharmacol Toxicol. 2014;114(1):97–102.PubMedCrossRef
18.
Moussa O, Ardissino M, Muttoni S, et al. Long-term incidence and outcomes of obesity-related peripheral vascular disease after bariatric surgery. Langenbecks Arch Surg. 2021;406(4):1029–36.PubMedPubMedCentralCrossRef
19.
Carmona-Maurici J, Cuello E, Sánchez E, et al. Impact of bariatric surgery on subclinical atherosclerosis in patients with morbid obesity. Surg Obes Relat Dis. 2020;16(10):1419–28.PubMedCrossRef
20.
Farias G, Netto BDM, Boritza K, et al. Impact of weight loss on inflammation state and endothelial markers among individuals with extreme obesity after gastric bypass surgery: a 2-year follow-up study. Obes Surg. 2020;30(5):1881–90.PubMedCrossRef
21.
Carmona-Maurici J, Cuello E, Ricart-Jané D, et al. Effect of bariatric surgery on inflammation and endothelial dysfunction as processes underlying subclinical atherosclerosis in morbid obesity. Surg Obes Relat Dis. 2020;16(12):1961–70.PubMedCrossRef
22.
23.
van den Berge M, van der Beek AJ, Türkeli R, et al. Work-related physical and psychosocial risk factors cluster with obesity, smoking and physical inactivity. Int Arch Occup Environ Health. 2021;94(4):741–50.PubMedPubMedCentralCrossRef
24.
Wang X, Sun H, Ma B, et al. Insulin-like growth factor 1 related to chronic low-grade inflammation in patients with obesity and early change of its levels after laparoscopic sleeve gastrectomy. Obes Surg. 2020;30(9):3326–32.PubMedCrossRef
25.
Paroutoglou K, Papadavid E, Christodoulatos GS, et al. Deciphering the association between psoriasis and obesity: current evidence and treatment considerations. Curr Obes Rep. 2020;9(3):165–78.PubMedCrossRef
26.
Liu Y, Jin J, Chen Y, et al. Integrative analyses of biomarkers and pathways for adipose tissue after bariatric surgery. Adipocyte. 2020;9(1):384–400.PubMedPubMedCentralCrossRef
27.
Min T, Prior SL, Dunseath G, et al. Temporal effects of bariatric surgery on adipokines, inflammation and oxidative stress in subjects with impaired glucose homeostasis at 4 years of follow-up. Obes Surg. 2020;30(5):1712–8.PubMedPubMedCentralCrossRef
28.
Chiappetta S, Schaack HM, Wölnerhannsen B, et al. The impact of obesity and metabolic surgery on chronic inflammation. Obes Surg. 2018;28(10):3028–40.PubMedCrossRef
29.
Tripathi D, Kant S, Pandey S, et al. Resistin in metabolism, inflammation, and disease. FEBS J. 2020;287(15):3141–9.PubMedCrossRef
30.
Biobaku F, Ghanim H, Monte SV, et al. Bariatric surgery remission of inflammation, cardiometabolic benefits, and common adverse effects. J Endocr Soc. 2020;4(9):bvaa049.PubMedPubMedCentralCrossRef
31.
Tchang BG, Saunders KH, Igel LI. Best practices in the management of overweight and obesity. Med Clin North Am. 2021;105(1):149–74.PubMedCrossRef
32.
American Diabetes Association. 8. Obesity Management for the treatment of type 2 diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S100–10.CrossRef
33.
Karlsson J, Galavazi M, Jansson S, et al. Effects on body weight, eating behavior, and quality of life of a low-energy diet combined with behavioral group treatment of persons with class II or III obesity: a 2-year pilot study. Obes Sci Pract. 2020;7(1):4–13.PubMedPubMedCentralCrossRef
34.
LeBlanc ES, Patnode CD, Webber EM, et al. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(11):1172–91.PubMedCrossRef
35.
De Luca M, Angrisani L, Himpens J, et al. Indications for surgery for obesity and weight-related diseases: position statements from the international federation for the surgery of obesity and metabolic disorders (IFSO). Obes Surg. 2016;26(8):1659–96.PubMedPubMedCentralCrossRef
36.
Dilektasli E, Demir B. Definitions and current indications for obesity and metabolic surgery. Ann Laparosc Endosc Surg. 2021;20(6):8.CrossRef
37.
Stahl JM, Malhotra S. Obesity surgery indications and contraindications. 2020 Jul 31. In: StatPearls. Treasure Island: StatPearls Publishing; 2021.
38.
Sümer A. Definition of obesity and current indications for obesity surgery. Laparosc Endosc Surg Sci. 2016;23(3):56–62.
39.
Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.PubMedPubMedCentralCrossRef
40.
Buchwald H, Consensus Conference Panel. Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis. 2005;1(3):371–81.PubMedCrossRef
41.
Ikramuddin S, Kendrick ML, Kellogg TA, et al. Open and laparoscopic Roux-en-Y gastric bypass: our techniques. J Gastrointest Surg. 2007;11(2):217–28.PubMedCrossRef
42.
Freitas WR Jr, Oliveira LVF, Perez EA, et al. Systemic inflammation in severe obese patients undergoing surgery for obesity and weight-related diseases. Obes Surg. 2018;28(7):1931–42.PubMedPubMedCentralCrossRef
43.
Arismendi E, Rivas E, Agustí A, et al. The systemic inflammome of severe obesity before and after bariatric surgery. PLoS One. 2014;9(9):e107859.PubMedPubMedCentralCrossRef
44.
Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375–91.PubMedCrossRef
45.
Tam CS, Redman LM. Adipose tissue inflammation and metabolic dysfunction: a clinical perspective. Horm Mol Biol Clin Invest. 2013;15(1):19–24.
46.
Illán-Gómez F, Gonzálvez-Ortega M, Orea-Soler I, et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg. 2012;22(6):950–5.PubMedCrossRef
47.
Chiappetta S, Jamadar P, Stier C, et al. The role of C-reactive protein after surgery for obesity and metabolic disorders. Surg Obes Relat Dis. 2020;16(1):99–108.PubMedCrossRef
48.
de Lima-Junior JC, Virginio VWM, Moura FA, et al. Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity. Nutr Metab Cardiovasc Dis. 2020;30(2):254–64.PubMedCrossRef
49.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.PubMedCrossRef
50.
Malheiros C, Freitas JRW, Saleh M, et al. Bariatric surgery decreases the inflammatory response in the 6 months post-operatory. Obes Surg. 2009;19:1013.
51.
Goktas Z, Moustaid-Moussa N, Shen CL, et al. Effects of bariatric surgery on adipokine-induced inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;10(4):69.
52.
Farkhondeh T, Llorens S, Pourbagher-Shahri AM, et al. An overview of the role of adipokines in cardiometabolic diseases. Molecules. 2020;25(21):5218.PubMedCentralCrossRef
53.
ParreñoCaparrós E, Illán Gómez F, Gonzálvez Ortega M, et al. Resistin in morbidly obese patients before and after gastric bypass surgery. Nutr Hosp. 2017;34(5):1333–7.
54.
Rodríguez-López CP, González-Torres MC, Cruz-Bautista I, et al. Visceral obesity, skeletal muscle mass and resistin in metabolic syndrome development. Nutr Hosp. 2019;36(1):43–50.PubMed
55.
Su KZ, Li YR, Zhang D, et al. Relation of circulating resistin to insulin resistance in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Physiol. 2019;19(10):1399.CrossRef
56.
Jamaluddin MS, Weakley SM, Yao Q, et al. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012;165(3):622–32.PubMedPubMedCentralCrossRef
57.
Fontana A, Spadaro S, Copetti M, et al. Association between resistin levels and all-cause and cardiovascular mortality: a new study and a systematic review and meta-analysis. PLoS One. 2015;10(3):e0120419.PubMedPubMedCentralCrossRef
58.
Wang YY, Hung AC, Lo S, et al. Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential. Cancer Lett. 2021;1(498):229–39.CrossRef
59.
Miethe C, Zamora M, Torres L, et al. Characterizing the differential physiological effects of adipocytokines visfatin and resistin in liver cancer cells. Horm Mol Biol Clin Investig. 2019;38(2):/j/hmbci.2019.38.issue-2/hmbci-2018-0068/hmbci-2018-0068.xml.PubMed
60.
Miethe C, Torres L, Beristain J, et al. The role of visfatin and resistin in an in vitro model of obesity-induced invasive liver cancer. Can J Physiol Pharmacol. 2020;23:1–8.
61.
62.
Zhang M, Yan L, Wang GJ, et al. Resistin effects on pancreatic cancer progression and chemoresistance are mediated through its receptors CAP1 and TLR4. J Cell Physiol. 2019;234(6):9457–66.PubMedCrossRef
63.
Qiu L, Zhang GF, Yu L, et al. Novel oncogenic and chemoresistance-inducing functions of resistin in ovarian cancer cells require miRNAs-mediated induction of epithelial-to-mesenchymal transition. Sci Rep. 2018;8(1):12522.PubMedPubMedCentralCrossRef
64.
Gong WJ, Zheng W, Xiao L, et al. Circulating resistin levels and obesity-related cancer risk: a meta-analysis. Oncotarget. 2016;7(36):57694–704.PubMedPubMedCentralCrossRef
65.
Edwards C, Hindle AK, Fu S, et al. Downregulation of leptin and resistin expression in blood following bariatric surgery. Surg Endosc. 2011;25(6):1962–8.PubMedCrossRef
66.
Martinelli CE Jr, Custódio RJ, Aguiar-Oliveira MH. Fisiologia do Eixo GH-Sistema IGF. Arq Bras Endrocrinol Metab. 2008;52(5):717–25.CrossRef
67.
Juiz-Valiña P, Pena-Bello L, Cordido M, et al. Altered GH-IGF-1 axis in severe obese subjects is reversed after bariatric surgery-induced weight loss and related with low-grade chronic inflammation. J Clin Med. 2020;9(8):2614.PubMedCentralCrossRef
68.
Pellitero S, Granada ML, Martínez E, et al. IGF1 modifications after bariatric surgery in morbidly obese patients: potential implications of nutritional status according to specific surgical technique. Eur J Endocrinol. 2013;169(5):695–703.PubMedCrossRef
69.
Pardina E, Ferrer R, Baena-Fustegueras JA, et al. The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese. Obes Surg. 2010;20(5):623–32.PubMedCrossRef
70.
71.
Obradovic M, Zafirovic S, Soskic S, et al. Effects of IGF-1 on the Cardiovascular System. Curr Pharm Des. 2019;25(35):3715–25.PubMedCrossRef
72.
Dichtel LE, Corey KE, Misdraji J, et al. The association between igf-1 levels and the histologic severity of nonalcoholic fatty liver disease. Clin Transl Gastroenterol. 2017;8(1):e217.PubMedPubMedCentralCrossRef
73.
Sádaba MC, Martín-Estal I, Puche JE, et al. Insulin-like growth factor 1 (IGF-1) therapy: Mitochondrial dysfunction and diseases. Biochim Biophys Acta. 2016;1862(7):1267–78.PubMedCrossRef
74.
Olleros Santos-Ruiz M, Sádaba MC, Martín-Estal I, et al. The single IGF-1 partial deficiency is responsible for mitochondrial dysfunction and is restored by IGF-1 replacement therapy. Growth Horm IGF Res. 2017;35:21–32.PubMedCrossRef
75.
Rasmussen MH, Juul A, Hilsted J. Effect of weight loss on free insulin-like growth factor-I in obese women with hyposomatotropism. Obesity (Silver Spring). 2007;15(4):879–86.CrossRef
76.
77.
Sumarac-Dumanovic M, Stevanovic D, Ljubic A, et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes (Lond). 2009;33(1):151–6.CrossRef
78.
Neurath MF. IL-23 in inflammatory bowel diseases and colon cancer. Cytokine Growth Factor Rev. 2019;45:1–8.PubMedCrossRef
79.
Yan J, Smyth MJ, Teng MWL. Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer. Cold Spring Harb Perspect Biol. 2018;10(7):a028530.PubMedPubMedCentralCrossRef
80.
Chyuan IT, Lai JH. New insights into the IL-12 and IL-23: from a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem Pharmacol. 2020;175:113928.PubMedCrossRef
81.
Ge W, Hu H, Cai W, et al. High-risk stage III colon cancer patients identified by a novel five-gene mutational signature are characterized by upregulation of IL-23A and gut bacterial translocation of the tumor microenvironment. Int J Cancer. 2020;146(7):2027–35.PubMedCrossRef
82.
Hirano T, Hirayama D, Wagatsuma K, et al. Immunological mechanisms in inflammation-associated colon carcinogenesis. Int J Mol Sci. 2020;21(9):3062.PubMedCentralCrossRef
83.
Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15(9):1016–22.PubMedPubMedCentralCrossRef
Metadaten
Titel
Surgery for Obesity and Weight-Related Diseases Changes the Inflammatory Profile in Women with Severe Obesity: a Randomized Controlled Clinical Trial
verfasst von
Alan Robson Trigueiro de Sousa
Wilson Rodrigues Freitas Junior
Eduardo Araujo Perez
Elias Jirjoss Ilias
Anderson Soares Silva
Vera Lucia Santos Alves
João Pedro Ribeiro Afonso
Miriã Cândida Oliveira
Adriano Luís Fonseca
Marcos Mota da Silva
Maria Eduarda Moreira Lino
Manoel Carneiro Oliveira Junior
Rodolfo Paula Vieira
Wilson José Sena Pedro
André Luis Lacerda Bachi
Giuseppe Insalaco
Carlos Alberto Malheiros
Luis Vicente Franco Oliveira
Publikationsdatum
23.09.2021
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 12/2021
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-021-05702-5

Weitere Artikel der Ausgabe 12/2021

Obesity Surgery 12/2021 Zur Ausgabe

Multimedia Article

Laparoscopic Management of Jejuno-jejunal Intussusception Post Laparoscopic Roux-en-Y Gastric Bypass in a Pregnant Patient

Letter to Editor/LED Reply

Letter to the Editor: Do Not Throw the Band Out with the Bath Water

Original Contributions

Effect of Ultrasound-Guided Erector Spinae Plane Block on Postoperative Pain and Intraoperative Opioid Consumption in Bariatric Surgery

Review

“What Really Matters When Performing a Laparoscopic Roux-en Y Gastric Bypass?” Literature-Based Key Steps Towards Success and Standardization of the Procedure

Original Contributions

Religious Fasting of Muslim Patients After Metabolic and Bariatric Surgery: a Modified Delphi Consensus

Original Contributions

Retrospective Comparison of SADI-S Versus RYGB in Chinese with Diabetes and BMI< 35kg/m2: a Propensity Score Adjustment Analysis

Neu im Fachgebiet Chirurgie

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise